C ommunity-acquired pneumonia (CAP) is a significant cause of morbidity and mortality (1) (2) (3) (4) . For a correct allocation of hospitalized patients, the Infectious Disease Society of America (IDSA) and the American Thoracic Society (ATS) have issued guidelines on the management of CAP that include specific criteria to identify patients to receive intensive care unit (ICU) care (5) . The accuracy of these criteria was prospectively validated for the first time in a large cohort of patients with CAP (6) .
The major criteria of the IDSA/ATS guidelines refer to patients with acute respiratory failure requiring invasive mechanical ventilation or septic shock. Determining the site of care of patients with one or more minor severity criteria is more difficult. The IDSA/ATS guidelines recommended that the presence of three or more of the nine minor criteria would indicate ICU admission (5) . Subsequent studies have confirmed the moderate predictive capacity of these minor criteria (7, 8) . However, no previous studies focused on those patients initially allocated in a ward and subsequently transferred to an ICU after deterioration. The proper use of resources for critically ill patients is important to avoid either unnecessary occupation of ICU beds or the increased mortality associated with delayed ICU admission (9, 10) .
The role of inflammatory biomarkers in the diagnosis, management, and outcome of infections, particularly procalcitonin and C-reactive protein (CRP), has been recently investigated (11, 12) . Added to the traditional criteria of infection, inflammatory biomarkers may help in the diagnosis, prognosis, and assessment of evolution of patients with CAP (13) (14) (15) . A less explored aspect of inflammatory biomarkers is their potential role to indicate the hospital location of patients depending on the severity of infection.
We hypothesized that increased systemic inflammation assessed by serum levels of biomarkers in the initial assessment of CAP may help clinicians to identify severe patients who will require ICU admission. We therefore determined whether serum levels of biomarkers can improve the prediction for ICU admission of the severity criteria defined by the IDSA/ATS guidelines (5) in patients with CAP and whether these determinations could reduce the number of patients initially allocated to wards who should be subsequently transferred to an ICU. We also assessed the relationship between biomarkers and patients' outcomes.
METHODS
Study Population. We prospectively followed consecutive patients aged Ն16 yrs hospitalized with a diagnosis of CAP who underwent a detailed study of inflammatory biomarkers at Hospital Universitario La Fe, Valencia, and Hospital Clínic, Barcelona, Spain, from January 2003 to October 2005.
Pneumonia was defined as a new pulmonary infiltrate on the admission chest radiograph and symptoms and signs of lower respiratory tract infection. Exclusion criteria were hospitalization in the previous 15 days, immunosuppressive therapy or systemic corticosteroids (Ͼ15 mg/ day), leukopenia (Ͻ1000 mm Ϫ3 ), or neutropenia (Ͻ500 mm
Ϫ3
) not attributed to pneumonia and patients with do-not-resuscitate orders. The study was approved by the ethics committees of both hospitals. The decision for admission to an ICU or ward was made by the attending physicians.
Determination of Cytokines, CRP, and Procalcitonin. Blood samples were taken within the first 24 hrs after admission, centrifuged, and frozen at Ϫ80°C. Determination of interleukin (IL)-1, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-␣ was performed with a commercial enzyme immunoassay technique (BioSource, Nivelles, Belgium). Limits of detection were 2 pg/mL for IL-6, 0.7 pg/mL for IL-8, 1 pg/mL for IL-10, and 2 pg/mL for TNF-␣ and IL-1. An immunoluminometric technique was used to measure procalcitonin (Liaison Brahms PCT; DiaSorin, Saluggia, Italy) with a detection limit of 0.04 ng/mL and a functional sensitivity of 0.3 ng/ mL. CRP was measured using a commercially immunoturbidimetric method (Bayer Diag- nostics, Leverkusen, Germany) with an Advia 2400 (detection limit 0.1 mg/dL).
Data Collection and Definitions. The following parameters present at admission were recorded: age, gender, tobacco, alcohol and drug consumption, comorbidities (heart, renal, liver, lung, neurologic and neoplastic disease, diabetes mellitus), previous antibiotics (in the preceding 90 days), treatment with inhaled and oral corticosteroids, clinical symptoms and features (fever, cough, pleuritic chest pain, dyspnea, mental confusion, aspiration), clinical signs (blood pressure, body temperature, respiratory rate, heart rate), arterial blood gases, chest radiograph, laboratory parameters, diagnostic procedures, and therapy. Septic shock (16) , need for mechanical ventilation, complications, length of stay, and hospital mortality were noted. We calculated the Pneumonia Severity Index (17) at admission.
According to the IDSA/ATS guidelines (5), those cases that met at least one of two major criteria or three of nine minor criteria at admission were defined as severe CAP. The reported criteria for severe CAP were obtained within 24 hrs of admission in the emergency room.
Inflammatory Biomarkers, ICU Admission, and Outcome. We compared the serum levels of biomarkers taken at hospital admission between ICU and ward patients from the overall population. Because the need for ICU admission in patients with septic shock or needing invasive mechanical ventilation is self-evident, we excluded patients with major severity criteria (5) in all predictions for ICU admission.
As a result of the potential bias derived from the association between inflammatory biomarkers and different severity of ICU and non-ICU patients, we also performed a case-control study with ICU (cases) and non-ICU patients (control subjects) matched by age, comorbidities, and Pneumonia Severity Index risk class (17) to adjust ICU and non-ICU patients for these parameters. We assessed if serum levels of biomarkers can identify: 1) ICU admission, by comparing cases and control subjects; and 2) delayed ICU admission, by comparing control patients and cases initially allocated to a ward and transferred to an ICU after clinical deterioration.
The predictive capacity for ICU admission and delayed ICU admission was determined for all biomarkers and the minor criteria for severe CAP of the IDSA/ATS guidelines (5).
We also compared the serum levels of biomarkers and other factors potentially related with inflammatory response or mortality in survivors and nonsurvivors.
Statistical Analysis. Qualitative or categorical variables were compared between groups with the chi-square or Fisher's exact test when appropriate. Quantitative continuous variables were compared using the Student's t test or nonparametric Mann-Whitney test when appropriate.
The predictive capacity for ICU admission and delayed ICU admission of the serum levels of inflammatory biomarkers and the IDSA/ATS guidelines minor criteria for severe CAP were assessed and compared with receiver operating characteristics curves; the area under the curve, optimal cutoff values, odds ratio and 95% confidence interval, sensitivity, specificity, and positive and negative likelihood ratios (18) were calculated. Data were processed with SPSS 16.0 (SPSS Inc, Chicago, IL). The level of significance was set at 0.05 (two-tailed).
RESULTS

Patients.
We included 685 consecutive patients with CAP; 627 were managed in a Rates of severe community-acquired pneumonia by Infectious Disease Society of America/American Thoracic Society criteria, need for invasive and noninvasive ventilation, and septic shock at presentation to the emergency department in patients with delayed intensive care unit admission. In the remaining cases, the criteria for severe community-acquired pneumonia, including intubation and septic shock, as well as the need for noninvasive ventilation appeared after initial ward admission; Tables 1  and 2 show the main characteristics of patients. The ICU patients were more often smokers, had received less frequently prior antibiotics, their Pneumonia Severity Index risk classes were higher, and an etiologic diagnosis was achieved more often.
One hundred twenty-five (18%) patients had severe CAP according to the IDSA/ATS guidelines (5); this was more frequent in ICU patients ( Table 2 
Patients with delayed ICU admission had longer hospital stay than those with direct ICU admission (p Ͻ .001) without any other significant difference (Table 3) .
Inflammatory Biomarkers and ICU Admission. The serum levels of CRP, Procalcitonin, TNF-␣, and IL-6 at admission in the overall population without major severity criteria were higher in ICU patients (Table 4) . Likewise, the serum levels of these biomarkers increased as the number of minor criteria of severe CAP increased, although the differences achieved statistical significance for procalcitonin and IL-6 only (Fig. 1) . The minor criteria (at least three of nine) for severe CAP of the IDSA/ATS guidelines (5) predicted ICU admission more accurately than biomarkers (Table 5) .
Seventy-eight patients had severe CAP as a result of minor criteria (three or more minor criteria in absence of major criteria). Among them, no patient with procalcitonin levels below the cutoffs shown in Table 5 needed ICU admission compared with 14 (23%, nine with direct and five with delayed ICU admission) patients with procalcitonin levels above the optimal cutoff (p ϭ .032). Similarly, one (4%) patient with IL-6 levels below the cutoff needed ICU admission compared with 13 (25%, nine with direct and four with delayed ICU admission) patients with procalcitonin and IL-6 levels above the optimal cutoffs (p ϭ .030).
On the other hand, ten patients without severe CAP criteria were admitted to the ICU according to the attending physicians; eight and six had procalcitonin and IL-6, respectively, levels above their cutoff values for ICU admission. None of them died in the hospital.
Inflammatory Biomarkers and Prediction of Delayed ICU Admission. In the case-control study, we could successfully match 56 of the 58 ICU patients (36 with direct and 20 with delayed ICU admission) with 56 control ward patients. The serum levels of CRP and procalcitonin were significantly higher in ICU compared with non-ICU patients adjusted for age, comorbidities, and Pneumonia Severity Index risk class (Fig. 2 ) without significant differences in the remaining biomarkers. Both biomarkers remained significantly higher in patients initially located in wards and subsequently transferred to an ICU after deterioration compared with control ward patients (Fig. 3) , indicating higher systemic inflammation at admission. By contrast, the serum levels of all biomarkers were similar between patients with direct and delayed ICU admission. The prediction for delayed ICU admission of the minor severity criteria of the IDSA/ATS guidelines, procalcitonin, and CRP are shown in Table 6 .
Despite the initial clinical decision for ward location, 15 (68%) patients with delayed ICU admission had already criteria for severe CAP by IDSA/ATS criteria at admission to the emergency room compared with 77 (12%, p Ͻ .001) in ward patients. Among the nine minor criteria, multilobar involvement, PaO 2 /FIO 2 Ͻ250 mm Hg, systolic blood pressure Ͻ90 mm Hg, respiratory rate Ͼ30 breaths/min, and leukopenia were significantly more frequent in patients with delayed ICU admission than ward patients. By contrast, mental confusion, thrombocytopenia, hypothermia, and blood urea nitrogen Ͼ20 mg/dL were similarly frequent among patients from both groups. c in all cases, significant differences were between non-ICU and both ICU groups without significant differences between direct and delayed ICU admission.
Inflammatory Biomarkers and Other
Factors Associated With Hospital Mortality. The serum levels of CRP, procalcitonin, TNF-␣, IL-6, and IL-8 were significantly higher in patients who died in the hospital (Table 7) . In addition to the criteria for severe CAP of the IDSA/ATS guidelines (5), other variables significantly associated with hospital mortality were older age, higher Pneumonia Severity Index risk class, and underlying neurologic disease.
DISCUSSION
Increased systemic inflammation assessed by higher serum levels of procalcitonin, CRP, TNF-␣, and IL-6 were higher in ICU patients with CAP. Although biomarkers did not improve the overall prediction for ICU admission of the IDSA/ATS guidelines (5), low levels of procalcitonin discarded ICU admission in patients with minor severity criteria. In initially ward patients, procalcitonin and CRP levels were higher in those subsequently transferred to ICU after deterioration. However, most of them had already criteria for severe CAP at admission according to the IDSA/ATS guidelines.
C-reactive protein (19) helps establish the diagnosis of CAP in patients with lower respiratory tract infections (20) . Adding CRP levels to the usual severity scales improves mortality prediction (15) and decisions regarding the appropriateness of inpatient care of CAP (20) . Procalcitonin is a reliable marker of bacteremia in patients with fever (21) and CAP (22) . Low levels of procalcitonin can identify patients with CAP at low risk of death (14) and helps for risk stratification (23) . Decreased serial levels of CRP and procalcitonin help predict the absence of severe complications (24, 25) and allow for a more rational use of antibiotics (26) . Interleukin-6 is another reliable marker of infection in patients with pulmonary infiltrates and suspected ventilator-associated pneumonia (27) . Elevated levels of IL-6 also predict poor outcome in pneumonia (28 -31) . Other biomarkers have been studied in patients with CAP (13).
The mortality of severe CAP is still very high ranging from 15% to 30% (7, 9, 10, 32) . The early detection of patients who need ICU admission is a simple clinical task when patients are in septic shock or need invasive mechanical ventilation. By contrast, there are some patients in whom the severity is higher than that apparently shown who could benefit from an early ICU admission. For that reason, the IDSA/ATS released a series of nine minor criteria to detect these types of patients (5) . Previous studies (6 -8) clinically validated these minor criteria. Although the accuracy was reasonable, they were not perfect; particularly a significant proportion of patients with severe CAP by minor criteria did not actually need ICU admission in a large population (6) .
Because the role of inflammatory biomarkers to identify patients with CAP who require ICU admission had not been previously assessed, we investigated in our study the potential use of serum levels of biomarkers in patients with minor severity criteria. The serum levels of procalcitonin, CRP, TNF-␣, and IL-6 at admission did not improve the overall accuracy of the minor severity criteria of the IDSA/ATS guidelines to decide ICU admission. Therefore, we cannot strongly recommend these determinations alone for the site-of-care decision of hospitalized patients with CAP. However, in patients from our series with severe CAP resulting from minor criteria, low serum levels of procalcitonin and IL-6 at hospital admission identified those who may be safely managed out of the ICU.
The low negative likelihood ratio of procalcitonin to predict ICU admission (Table 5) indicates that patients with low levels of this biomarker are unlikely to require ICU admission. These findings may help in optimizing the use of ICU resources, which are often scarce in many institutions. By contrast, higher serum levels of procalcitonin and IL-6, above the cutoff, did not discriminate between patients who needed ICU admission or not and therefore were not helpful in identifying patients who will require intensive care. Delayed ICU admission for any cause may occur in at least 30% patients with severe CAP (9) . Delayed ICU admission was associated with two-to 2.6-fold increased risk for hospital mortality in two recent studies compared with direct admission from the emergency room (9, 10) . Both studies advised further research to identify patients who may benefit from direct ICU admission. In line with these publications, we also investigated in our study the potential use of serum levels of biomarkers in patients with delayed ICU admission. In our patients initially located in wards, higher levels of CRP and procalcitonin predicted further deterioration and the need for ICU transfer.
Interestingly, 64% patients with delayed ICU admission from our study had already criteria for severe CAP at admission. Applying accurately the IDSA/ATS guidelines in combination with serum levels of procalcitonin would minimize the wrong initial location of patients and the potential increase in mortality associated with delayed ICU admission. However, not all the minor criteria were significantly associated with delayed ICU transfer in those patients initially located in wards. Therefore, larger populations of patients are needed to determine the individual weight of each minor severity criteria to discriminate patients who would subsequently deteriorate and need ICU transfer. This might help to minimize unnecessary ICU admission of patients who may progress well in the ward.
As expected and in accordance with previous studies (14, 15) , higher levels of serum biomarkers in the overall population were associated with hospital mortality. In those patients initially located in wards, these associations persisted for procalcitonin, IL-6 and IL-8, but not for TNF-␣, whereas differences in CRP levels were in the limits of statistical significance.
Several limitations need to be addressed. First, we processed one single blood sample for biomarker assessment. Although samples were collected as soon as possible in the emergency department when triage decisions are being made, several of these biomarkers can substantially change along time. Second, there were a relatively small number of ICU patients after excluding those with major severity criteria. Therefore, studies on larger series are advisable to confirm these results.
CONCLUSION
Inflammatory biomarkers identified patients needing ICU admission, including those with delayed ICU admission. Although the accuracy of the minor severity criteria of the IDSA/ATS guidelines to predict ICU admission was better than biomarkers alone, patients with severe CAP by minor criteria and low levels of procalcitonin may be safely admitted to wards. Combining procalcitonin levels with the correct application of these guidelines would reduce substantially delayed ICU admission. 
